Table 1 D’Amico risk stratification for localised cancer

From: Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme

Low risk

PSA<10 ng ml−1 and Gleason score=6 and clinical stage T1c or T2a

Intermediate risk

PSA>10 ng ml−1, but<20 ng ml−1, or Gleason score=7 or clinical stage T2b

High risk

PSA>20 ng ml−1 or Gleason score 8–10 or clinical stage T2c or T3

  1. Abbreviation: PSA=prostate specific antigen level.
Back to article page